Press release content from Accesswire. The AP news staff was not involved in its creation.
XPhyto Announces Psychedelic Pharmaceutical Production Agreement
February 3, 2021 GMT
VANCOUVER, BC / ACCESSWIRE / February 3, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories Inc. (“XPhyto Labs”), its wholly owned Alberta subsidiary, has signed an agreement (the “Agreement”) with Applied Pharmaceutical Innovation (“Applied”) for the synthesis of pharmaceutical grade psychedelic compounds and the parallel development of the standard operating procedures necessary to obtain regulatory approval for the respective commercial production process. The industrial-scale production of standardized active pharmaceutical ingredients is an important part of XPhyto’s psychedelic pharmaceutical program as the Company anticipates a shortage of large-scale supply of certain approved and standar
XPhyto Therapeutics Corp.: XPhyto Announces Psychedelic Pharmaceutical Production Agreement
XPhyto Therapeutics Corp. (
XPhyto or the
Company ) is pleased to announce that XPhyto Laboratories Inc. ( XPhyto Labs ), its wholly owned Alberta subsidiary, has signed an agreement (the Agreement ) with Applied Pharmaceutical Innovation ( Applied ) for the synthesis of pharmaceutical grade psychedelic compounds and the parallel development of the standard operating procedures necessary to obtain regulatory approval for the respective commercial production process. The industrial-scale production of standardized active pharmaceutical ingredients is an important part of XPhyto s psychedelic pharmaceutical program as the Company anticipates a shortage of large-scale supply of certain approved and standardized pharmaceutical grade psychedelics.